ZSP1273 clinical trials
Also written ZSP1273.
How each study uses ZSP1273 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2023 (6)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2023 | 6 |
| 2024 | 2 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 14 · Other 0
Guangdong Raynovent Biotech Co., Ltd (13) · Guangdong Zhongsheng Pharmaceutical Co., Ltd. (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses ZSP1273 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- Efficacy and Safety of ZSP1273 in Adolecent 12-17 Years Old With Influenza ACompletedPhase 3Guangdong Raynovent Biotech Co., LtdNCT07229820Written as ZSP1273
- Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza ACompletedPhase 3Guangdong Raynovent Biotech Co., LtdNCT07229807Written as ZSP1273
- Pharmacokinetics,Safety and Efficacy of ZSP1273 in Children 2-17 Years Old With Influenza ACompletedPhase 2Guangdong Raynovent Biotech Co., LtdNCT06656026Written as ZSP1273 granules
- Mass Balance Study of [14C]ZSP1273 in Healthy Adult Male Subjects in ChinaCompletedPhase 1Guangdong Raynovent Biotech Co., LtdNCT05873426Written as [14C] ZSP1273
- Pharmacokinetics of ZSP1273 in Participants With Severe Kidney DiseaseCompletedPhase 1Guangdong Raynovent Biotech Co., LtdNCT06248567Written as ZSP1273
- Bioavailability Study in Healthy Participants, 200mg Tablets ZSP1273 Versus 200mg Granules ZSP1273CompletedPhase 1Guangdong Raynovent Biotech Co., LtdNCT06164431Written as ZSP1273 tablet
- Drug-durg Interaction of ZSP1273 With Digoxin, Rosuvastatin,Itraconazole and ProbenecidCompletedPhase 1Guangdong Raynovent Biotech Co., LtdNCT05954624Written as ZSP1273
- A Drug Interaction Study Assess the Effects of ZSP1273 Tablets on the Pharmacokinetics of Warfarin and MidazolamCompletedPhase 1Guangdong Raynovent Biotech Co., LtdNCT05942365Written as ZSP1273
- Pharmacokinetics of ZSP1273 in Elder ParticipantsCompletedPhase 1Guangdong Raynovent Biotech Co., LtdNCT06157450Written as ZSP1273
- Pharmacokinetics of ZSP1273 in Participants With Hepatic ImpairmentCompletedPhase 1Guangdong Raynovent Biotech Co., LtdNCT05856513Written as ZSP1273
- A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza ACompletedPhase 3Guangdong Raynovent Biotech Co., LtdNCT04683406Written as ZSP1273 600 mg
- Study to Investigate the Potential Drug-Drug Interaction Between ZSP1273 and OseltamivirCompletedPhase 1Guangdong Raynovent Biotech Co., LtdNCT05108051Written as ZSP1273
- Study of ZSP1273 in Patients With Acute Uncomplicated Influenza ACompletedPhase 2Guangdong Raynovent Biotech Co., LtdNCT04024137Written as ZSP1273 200 mg
- The Safety, Tolerability and Pharmacokinetic Study of ZSP1273 in Healthy Volunteers.CompletedPhase 1Guangdong Zhongsheng Pharmaceutical Co., Ltd.NCT03679143Written as ZSP1273 100 mg